Hyderabad-based Dr Reddy's Laboratories (DRL ... time adjustments related to the acquisition of the Nicotine Replacement ...

By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with ...

The U.S. unit of Indian drugmaker Dr. Reddy’s Laboratories is recalling 331,590 bottles of cinacalcet tablets used to treat hyperparathyroidism due to the presence of a known carcinogen. | The U.S.

According to the latest Enforcement Report by the US Food and Drug Administration, Dr Reddy's is recalling the 3,31,590 ...

I was alarmed by a recent Star guest commentary that leveled a number of false attacks against Dr. Prasanth Reddy. The ...

Haleon To Offload Non-Core Nicotine Therapy Business To Dr. Reddy's For Over $600M Haleon has agreed to sell its nicotine replacement therapy business outside the U.S. to Dr. Reddy's Laboratories ...

Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Nizamabad: Dr J. Bapu Reddy, a founding member of the BRS and a renowned physician, died on Saturday night in Hyderabad after a prolonged battle with ill health. He was 75 years old. For the past ...

Anvita Reddy (she/her) is an assistant editor for PS Shopping. She has a passion for products and reviews home gadgets, cookware, tech, and more. Having dealt with acne as a teenager and into ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...